• Risk factors of bleeding in adult immune thrombocytopenia are not known.
Essentials
• Risk factors of bleeding in adult immune thrombocytopenia are not known.
• This multicenter study assessed risk factors of bleeding at immune thrombocytopenia onset.
• Platelet count thresholds associated with bleeding were < 20 9 10 9 L À1 and < 10 9 10 9 L À1 .
• Exposure to anticoagulants was a major risk factor of severe bleeding.
Summary. Background:
The aim of this cross-sectional study was to assess risk factors for bleeding in immune thrombocytopenia (ITP) adults, including the determination of platelet count thresholds. Methods: We selected all newly diagnosed ITP adults included in the Cytop enies Auto-immunes Registre Midi-Pyr en eEN (CARMEN) register and at the French referral center for autoimmune cytopenias. The frequencies of any bleeding, mucosal bleeding and severe bleeding (gastrointestinal, intracranial, or macroscopic hematuria) at ITP onset were assessed. Platelet count thresholds were assessed by the use of receiver operating characteristic curves. All potential risk factors were included in logistic regression models. Results: Among the 302 patients, the frequencies of any, mucosal and severe bleeding were 57.9%, 30.1%, and 6.6%, respectively. The best discriminant threshold of platelet count for any bleeding was 20 9 10 9 L
À1
. In multivariate analysis, factors associated with any bleeding were platelet count (< 10 , OR 5.2, 95% CI 2.3-11.6), female sex (OR 2.6, 95% CI 1.3-5.0), and exposure to non-steroidal anti-inflammatory drugs (NSAIDs) (OR 4.8, 95% CI 1.1-20.7). A low platelet count was also the main risk factor for mucosal bleeding. Exposure to anticoagulant drugs was associated with severe bleeding (OR 4.3, 95% CI 1.3-14.1). Conclusions: Platelet counts of < 20 9 10 9 L À1 and < 10 9 10 9 L À1 were thresholds for major increased risks of any and mucosal bleeding. Platelet count, female sex and exposure to NSAIDs should be considered for assessment of the risk of any bleeding. Exposure to anticoagulant drugs was a major risk factor for severe bleeding.
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Introduction
Immune thrombocytopenia (ITP) is a rare autoimmune disease characterized by a platelet count of < 100 9 10 9 L À1 with exclusion of the other causes of thrombocytopenia [1] . autoimmune platelet destruction, with impaired platelet production [2] . Bleeding is a main cause of morbidity and mortality in adult ITP patients [3] . In adults, treatment is indicated if there is a low platelet count even in the absence of bleeding. Most guidelines recommend a threshold of < 30 9 10 9 L À1 for initiation of treatment [4] [5] [6] . The criteria proposed for response to treatment also include a platelet count of ≥ 30 9 10 9 L
À1
, on the assumption that it prevents significant bleeding [1] . This threshold stems from an epidemiological study published in 1991. The authors assessed the bleeding risk in a population of 117 patients with chronic ITP, with a 30-month median follow-up (range: 6-76 months) [7] . Eighteen major bleeds (defined by requiring hospital admission or clinically overt with a decrease in hemoglobin level of at least 20 g L À1 ) occurred: eight at ITP diagnosis and 10 during follow-up. Fourteen occurred with a platelet count of < 20 9 10 9 L À1 , four with a platelet count between 20 9 10 9 L À1 and 30 9 10 9 L
, and none with a platelet count of > 30 9 10 9 L
. There was no adjustment for treatment exposure or other covariates in this study.
This platelet count threshold is debated. On the basis of their experience, some authors recommend other thresholds, as low as 10 9 10 9 L À1 [8] . Conversely, two case series (one in children and one in adults) suggested that intracranial bleeding could occur with platelet counts above 30 9 10 9 L À1 , suggesting that other factors may impact on the risk of severe bleeding [9, 10] . Moreover, some guidelines recommend raising the platelet count target in cases with comorbidities, older age, and exposure to antiplatelet or anticoagulant drugs [5, 6] . However, few data are available regarding other potential risk factors for bleeding in adult ITP patients. Older age has been linked to severe bleeding by several studies [11] [12] [13] , but there is a lack of studies assessing the bleeding risk in ITP adults adjusted for other potential risk factors and platelet count.
The aim of this study was to identify the risk factors for any bleeding, mucosal bleeding and severe bleeding in ITP adults at the time of diagnosis, including the determination of platelet count thresholds.
Methods

Design
We conducted a cross-sectional study at ITP diagnosis within clinical registries.
Data source
The data source was the combination of two registers: the Cytop enies Auto-immunes Registre Midi-Pyr en eEN (CAR-MEN) register, and the register of the French referral center for autoimmune cytopenias in Cr eteil.
The CARMEN register is a multicenter register aimed at following all ITP adults in the Midi-Pyr en ees region (southwest of France, 3 million inhabitants) newly diagnosed since June 2013 (NCT02877706) [14, 15] . Patients are included at ITP diagnosis in the 22 centers of the region hosting an internal medicine or a hematology department managing ITP patients (in 19 public hospitals and three private hospitals). Inclusion criteria in the register are: (i) age ≥ 18 years; (ii) incident ITP defined according to 2009 French guidelines as a platelet count of < 150 9 10 9 L À1 and exclusion of the other causes of thrombocytopenia [16] ; and (iii) follow-up in the region. Each investigator includes every newly diagnosed ITP patient that he or she cares for, and collects clinical and laboratory data, including all of the variables used in this study, which were collected at the time of ITP diagnosis. Follow-up is then based on real-life practice [14] .
Since November 2015, all newly diagnosed ITP adults at the French referral center for autoimmune cytopenias (covering the Paris Southeast area) have been included in a register using the same methodology and database as in the CARMEN register. There was no overlap between the two registries of patients included in the present study.
Study population
We selected all patients included between June 2013 and March 2017 in the CARMEN register, and those included between November 2015 and March 2017 in the French referral center for autoimmune cytopenias register. In order to fit international guidelines [1] , patients with platelet counts of ≥ 100 9 10 9 L À1 were excluded. In the main analysis, both primary and secondary ITPs were included. Sensitivity analyses restricted to primary ITPs were conducted.
Outcomes
Three outcomes were assessed: any bleeding (cutaneous, mucosal, or visceral), mucosal bleeding (epistaxis, gingival bleeding, or hemorrhagic oral bullae), and severe bleeding (defined by macroscopic hematuria, and gastrointestinal or intracranial bleeds). We included macroscopic hematuria among severe bleeding because it has been demonstrated to be a risk factor for intracranial hemorrhage in children with ITP [10] . Outcomes were assessed at ITP diagnosis in order to avoid confounders related to ITP treatment.
Covariates
We selected the following potential risk factors for bleeding: age (by quartiles), sex, history of arterial hypertension (blood pressure of ≥ 140/90 mmHg), history or current symptoms of peptic ulcer, Charlson Comorbidity Index [17] (categorized as follows: 0, 1, 2, and ≥ 3), primary versus secondary ITP, exposure to non-steroidal anti-inflammatory drugs (NSAIDs), exposure to antiplatelet drugs, exposure to anticoagulant drugs, exposure to serotonin reuptake inhibitors (SRIs), and platelet count at ITP diagnosis. All drug exposures were assessed at the time of ITP diagnosis, except for the exposure to NSAIDs that may be temporary and defined as any exposure during the 6 weeks preceding the first ITP symptoms (bleeding or abnormal platelet count).
Statistical analyses
We described the frequency of any bleeding, of mucosal bleeding and of severe bleeding at ITP diagnosis, overall, and by covariates.
To assess the association between platelet count and outcomes, we used receiver operating characteristic (ROC) curves and calculated the areas under the curves (AUCs). We also calculated the sensitivity and specificity for each platelet count threshold (by 5 9 10 9 L À1 up to 50 9 10 9 L À1 ). The best discriminant thresholds were defined as those having the best Youden index (sensitivity + specificity À 1) [18] . Finally, we assessed the factors associated with each of the three bleeding outcomes by using logistic regression models. All covariates listed above were included in the models, with the exception of the signs of peptic ulcer in the assessment of severe bleeding, because only one patient had symptoms suggestive of peptic ulcer in the group of patients with severe bleeding. Platelet count categories were derived from the thresholds found. Statistical analyses were performed with SAS V9.4 (SAS Institute, Cary, NC, USA).
Ethical considerations
The Toulouse University Hospital Ethics Committee gave approval (no. 27-0512). Authorization for data collection was obtained from the Comit e Consultatif sur le Traitement de l'Information en mati ere de Recherche dans le domaine de la Sant e (no. 12.067) and from the Commission Nationale de l'Informatique et des Libert es (no. DE-2012-438).
Results
Patient selection
During the study period, 292 newly diagnosed ITP adults were included in the CARMEN register and 56 in the French referral center for autoimmune cytopenias register. Forty-six patients were excluded: seven who refused to participate, one not followed in the Midi-Pyr en ees region, and 38 with a platelet count at ITP diagnosis of ≥ 100 9 10 9 L À1 . Consequently, 302 patients were included in the study.
Patient characteristics
Patient characteristics are shown in Table 1 . The median age at diagnosis was 66 years. Nearly half of the patients were females (49.7%), and 46.9% had a Charlson Comorbidity Index of ≥ 1 (8.0% had a Charlson Comorbidity Index of ≥ 3). Respectively, 59 (19.5%), 23 (7.6%), 23 (7.6%) and 20 (6.6%) patients were exposed to antiplatelet drugs, anticoagulant drugs, NSAIDs, and SRIs. Antiplatelet drugs were low-dose aspirin (n = 51) and clopidogrel (n = 13). Anticoagulant drugs were vitamin K antagonists (n = 15), direct oral anticoagulants (n = 5), low molecular weight heparin (n = 5), and unfractionated heparin (n = 1). Sixteen per cent of the patients (n = 48) had a secondary ITP, including eight with myelodysplastic syndrome, seven with lymphoma, six with Evans syndrome, eight with infections (six cytomegalovirus, two hepatitis C virus, and two HIV), and 10 with autoimmune diseases (including four with Sj€ ogren syndrome, two with systemic lupus erythematosus, and two with ulcerative colitis). The median platelet count at diagnosis was 18 9 10 9 L À1 (Q1-Q3: 5-50).
Outcomes
Bleeding symptoms occurred at ITP diagnosis in 175 (57.9%) patients, mucosal bleeding in 91 (30.1%) patients, and severe bleeding in 20 (6.6%) patients. The 20 severe bleeds are detailed in Table 2 . They consisted of four intracranial hemorrhages, eight gastrointestinal tract bleeds, and nine cases of macroscopic hematuria (one patient had both a gastrointestinal bleed and a hematuria). Eleven patients had other bleeding signs. Fifteen patients were males, and 50% were aged > 80 years. Only four patients had a platelet count of > 20 9 10 9 L
À1
: one patient with intracranial hemorrhage complicating a cavernoma, and three patients aged ≥ 80 years and exposed to an antithrombotic drug. Overall, 10 (50%) patients were exposed to an antithrombotic drug (anticoagulant, n = 5; antiplatelet drugs, n = 6) and three to NSAIDs. Among the nine patients with no other bleeding signs, six were aged ≥ 85 years (including five exposed to antiplatelet or anticoagulant drugs), and two younger patients had organ-related favoring factors (cerebral cavernoma in one patient with intracranial hemorrhage, and ulcerative colitis in one patient with gastrointestinal bleeding). Two patients died from complications of bleeding: a 59-year-old woman with Evans syndrome who died from an intracranial bleed, and an 86-year-old man with ischemic heart disease treated with clopidogrel who died from complications of macroscopic hematuria.
Bleeding symptoms by platelet count
The frequencies of any bleeding, of mucosal bleeding and of severe bleeding at ITP onset by platelet count are shown in Fig. 1 . Bleeding was more frequent in patients with a platelet count of < 20 9 10 9 L À1 : the frequency of any bleeding was 86.0% (135/157) in patients with a platelet count of < 20 9 10 9 L À1 versus 27.6% (40/145) in those with a platelet count of ≥ 20 9 10 9 L À1 . Bleeding was observed in 94.8% (110/116) of patients with a platelet count of < 10 9 10 9 L À1 . Mucosal bleeding was also more frequent in patients with a platelet count of < 20 9 10 9 L À1 (45.2% [71/157] than in those with a platelet count of ≥ 20 9 10 9 L À1 (13.8% [20/145] ). In contrast, this pattern was not observed for severe bleeding. ROC curves for the association of platelet count and bleeding are shown in Fig. 2 . There was a very good correlation between platelet count and the occurrence of any bleeding (AUC 84.5%, 95% confidence interval [CI] 80.1-89.0), and a good correlation with mucosal bleeding (AUC 74.2%, 95% CI 68.2-80.3); the correlation was poorer for severe bleeding (AUC 63.5%, 95% CI 51.7-75.2).
The sensibility, specificity and Youden index for platelet threshold are shown in Table 3 Analyses restricted to primary ITP gave similar results ( Fig. S1 ; Table S1 ).
Bleeding symptoms by other covariates
The frequencies of the three categories of bleeding by age, sex, Charlson Comorbidity Index and drug exposures are shown in Fig. 3 . Only slight differences were observed across age classes: any bleeding was less frequent in patients aged between 45 years and 64 years than in those aged < 45 years: 45.2% versus 65.3%. Severe bleeding was more frequent after 80 years than before 45 years: 11.5% versus 6.7%.
The frequency of any bleeding was higher in women (63.3% versus 52.6%), whereas the frequency of severe bleeding was higher in men (9.9% versus 3.3%). The frequency of bleeding did not change if patients had a history of arterial hypertension. Only slight differences were observed between Charlson Comorbidity Index groups, except for a low frequency of severe bleeding among patients with a Charlson Comorbidity Index of 0 (3.1%). There were increased frequencies of any bleeding and of mucosal bleeding in patients with exposure to NSAIDs (any bleeding, 82.6% versus 55.9%; mucosal bleeding, 43.5% versus 29.0%), and increased frequencies of severe bleeding in patients exposed to anticoagulant drugs (26.1% versus 5.0%) and SRIs (15.0% versus 6.0%). There were no remarkable difference in the frequencies of any bleeding, mucosal bleeding and severe bleeding according to exposure to antiplatelet drugs.
Risk factors for bleeding
The platelet count categories used in the models were derived from the Fig. 2 and ROC curve analyses. We chose the thresholds of < 10 9 10 9 L
À1
, between 10 9 10 9 L À1 and 19 9 10 9 L À1 and ≥ 20 9 10 9 L À1 for the assessment of any bleeding and of mucosal bleeding. For severe bleeding, we chose a unique threshold of < 20 9 10 9 L À1 , owing to the low number of observa-
tions.
The results are shown in Table 4 . In multivariate analysis, the platelet count at ITP diagnosis was associated with any bleeding (between 10 Only a low platelet count was associated with mucosal bleeding in multivariate analysis (Table 4) .
Finally, the factors associated with the occurrence of severe bleeding are shown in 
Discussion
This study demonstrated a good correlation between platelet count and the occurrence of any bleeding and of mucosal bleeding at ITP diagnosis in adults (before CI, confidence interval; ITP, immune thrombocytopenia; NSAID, non-steroidal anti-inflammatory drug; OR, odds ratio; SRI, serotonin reuptake inhibitor. CI, confidence interval; ITP, immune thrombocytopenia; NSAID, non-steroidal anti-inflammatory drug; OR, odds ratio; SRI, serotonin reuptake inhibitor. *The variable 'signs of peptic ulcer' was not included in this model, because only one patient had symptoms suggestive of peptic ulcer in the group with severe bleeding.
treatment), and a poorer correlation regarding the risk of severe bleeding. Platelet counts were independent risk factors for any bleeding and mucosal bleeding. Female sex and exposure to NSAIDs were associated with a higher risk of any bleeding. Factors associated with the risk of severe bleeding were exposure to anticoagulant drugs and, to a lesser extent, a platelet count of < 20 9 10 9 L À1 , male sex, and the presence of comorbidities. In contrast, antiplatelet drugs were not associated with bleeding occurrence. Interestingly, all patients with severe bleeding, except for one with macroscopic hematuria, had either other cutaneous bleeding manifestations, or local or general risk factors. The clinical characteristics of our population reflect real-life practice with older patients with comorbidities and multiple drug exposure, including antithrombotic drugs. The frequency of secondary ITPs (16.0%) was slightly lower than what has been published so far, but with an expected pattern [11, 19] .
Nearly two-thirds of the patients (56.0%) had bleeding events. This frequency is in accordance with that in previous UK cohorts [20, 21] . However, mucosal bleeding was more common in our cohort. The frequency of intracranial bleeding (1.3%) at diagnosis was also higher in our cohort than in the nationwide French population-based study by our group (0.4%) [11] . Similarly, a recent metaanalysis of 10 908 patients estimated the risk of intracranial bleeding at diagnosis to be 0.4% (95% CI 0.1-0.8) [12] . This discrepancy may be explained by the older age of our patients from the CARMEN register (almost onequarter of the whole cohort were aged > 80 years). These patients had comorbidities and increased exposure to antithrombotic drugs. It is of note that the huge increase in ITP incidence in the elderly has been previously demonstrated [11, 22] .
This study confirmed that platelet count is one of the main risk factors for bleeding in newly diagnosed ITP adults. Platelet counts of < 20 9 10 9 L À1 and < 10 9 10 9 L À1 were the thresholds associated with major increased risks for both any bleeding and mucosal bleeding at diagnosis. Most guidelines suggest a platelet count of 30 9 10 9 L À1 as the therapeutic threshold [4] [5] [6] 23] .
These guidelines stem from the previously quoted study from Cortelazzo et al. in 1991, which included chronic patients [7] . In our study, we included newly diagnosed patients only, and assessed the risk of bleeding before any exposure to treatment that may modify the risk of bleeding (by increasing platelet count or improving hemostasis in other ways). In 2001, Portielje et al. reported increased mortality in patients with chronic thrombocytopenia of < 30 9 10 9 L À1 as compared with the general population, with a relative risk of 4.2 (95% CI 1.7-10) [24] . However, other platelet count thresholds were not tested. In our study, the best discriminant threshold of platelet count for any bleeding was 20 9 10 9 L
À1
. However, the discriminant powers of platelet count thresholds were quite similar for any, mucosal and severe bleeding between 10 9 10 9 L À1 and 25 9 10 9 L À1 . Moreover, the correlation with platelet count was weaker for severe bleeding, even though 80% of patients with severe bleeding had a platelet count of < 20 9 10 9 L À1 . In 2013, Zhou et al. reported the results of a single-center study including 525 ITP patients aged ≥ 60 years in China [25] . They performed ROC curve analyses assessing the link between platelet count and bleeding at diagnosis as well as severe bleeding at diagnosis (defined by intracranial bleeding, oral mucosal bleeding, gastrointestinal bleeding, respiratory tract bleeding, hematuria, and menorrhagia). Using the sum of sensitivity and specificity as a criterion, they identified the best discriminant platelet count thresholds as being 29.5 9 10 9 L À1 and 21.5 9 10 9 L À1 , respectively. However, AUCs showed poor correlation, particularly for any bleeding.
In multivariate analyses, we found OR of 5.2 and 2.6 for any bleeding and mucosal bleeding, respectively, associated with platelet counts between 10 9 10 9 L À1 and 19 9 10 9 L À1 in comparison with ≥ 20 9 10 9 L À1 . These risks were highly increased in patients with a platelet count of < 10 9 10 9 L À1 . A platelet count of < 20 9 10 9 L À1 was also associated with severe bleeding with an OR of 2.6. Notably, it has been demonstrated that platelet function may be more correlated with bleeding than platelet count, particularly for severe bleeding [26] . The poor correlation that we observed in this study between platelet count and severe bleeding, as well as the impact of exposure to anticoagulant drugs on severe bleeding occurrence, in is support of this hypothesis. Notably, Lacey and Panner reported in 1977 that, among 138 thrombocytopenic patients with a variety of disorders, the risk of major bleeding was maximal with platelet counts of < 10 9 10 9 L À1 [27] . This finding has been confirmed more recently [28] . Regarding the other risk factors for bleeding, albeit including very old patients, this study did not demonstrate that age is a strong independent risk factor for bleeding. Although we found an increased risk of severe bleeding in patients aged > 80 years in univariate analysis (OR 2.53, 95% CI 1.01-6.35), this was less prominent after adjustment for other covariates, and particularly exposure to anticoagulant drugs (OR 1.54, 95% CI 0.53-4.48). This is in accordance with the few previous studies not adjusted for antithrombotic drug exposure that demonstrated an increase in the frequency of major bleeding in the elderly [7, 11, 13, 25] . Again, our results of multivariate analyses assessing the risk of severe bleeding should be considered with caution, owing to the lack of statistical power.
High blood pressure was not associated with bleeding occurrence. This is in accordance with the study by Michel et al., who included 55 ITP patients aged > 70 years and 97 younger patients [13] . However, we found an association between the presence of comorbidities and the occurrence of severe bleeding (OR 1.99, 95% CI 0.60-6.56).
The risk of any bleeding was increased among females. This had already been observed by Bizzoni et al. in 178 patients aged > 65 years: 52% of women experienced bleeding, as compared with 27% of men [29] . The increased risk of bleeding in females has been also demonstrated in other settings. Because genital bleeding was not reported in our study, and because the study by Bizzoni et al. included older women, other explanations should be searched for, such as hormone-related differences between males and females in small vessel wall resistance and hemostasis [30, 31] . Conversely, the risk of severe bleeding was increased in males even after adjustment for age and exposure to antithrombotic drugs, probably because of the pattern of severe bleeding observed, which included nine patients with hematuria and eight with gastrointestinal bleeding.
Exposure to anticoagulant drugs was highly associated with severe bleeding (OR 4.47, 95% CI 1.38-14.45). This association was not found in the case-control study by Melboucy-Belkhir et al., in which exposure to antithrombotic treatments did not differ between the group of 27 ITP cases with intracranial hemorrhage and the 54 controls [9] . However, this study was not limited to intracranial bleeding at ITP onset, and confounders during the ITP course may explain this result (e.g. the patients needing anticoagulant drugs may have been more closely monitored and more intensively treated for ITP).
Conversely, we did not find any association between exposure to antiplatelet drugs and bleeding occurrence, although 59 (19.5%) patients in our cohort were exposed to these drugs. This may be attributable to the high clearance of antiplatelet drugs bound to platelets in ITP. The impact of a high platelet turnover on a decreased effect of aspirin given daily on platelet function has been demonstrated in patients with essential thrombocythemia [32] . It is of note that our patients were mostly exposed to aspirin which is an irreversible antagonist with short half-life about (20 min) . The risk of bleeding may be different in ITP patients exposed to ticagrelor, a longhalf-life (8.5 h) reversible P2Y12 receptor inhibitor [33] .
Exposure to NSAIDs was associated with an increased frequency of any bleeding at ITP diagnosis. This discrepancy with antiplatelet drugs may be attributable to NSAID pharmacodynamics and pharmacokinetics, with, in contrast to aspirin, reversible binding to platelet cyclooxygenase 1 (COX-1), and longer half-lives of drugs and metabolites, resulting in lower sensitivity to high platelet turnover [34] . Importantly, in contrast to the other drugs evaluated in this study, exposure to NSAIDs was recorded in the registries as any exposure during the 6 weeks prior to ITP onset. Consequently, we cannot exclude the possibility of drug-induced ITPs [35] [36] [37] or a protopathic bias in cases of viral symptoms preceding ITP onset that may have led to more bleeding because of inflammation.
SRIs are thought to be responsible for an increased risk of bleeding, particularly gastrointestinal bleeding [39, 39] . In multivariate analyses, there was a weak association between SRIs and severe bleeding in this study. However, this result should be interpreted with regard to the very low number of patients exposed to SRIs and with gastrointestinal tract bleeding in our study.
This study has several limitations. First, even though both registries are intended to cover their geographical areas, we cannot ensure the completeness of case recording. However, the CARMEN register demonstrated an epidemiology of incident ITP similar to the epidemiology assessed by the use of population-based databases in France [11] . Second, because severe bleeding is a rare event in ITP patients, we lacked the power to estimate the risk factors associated with it. Our results need to be confirmed by larger studies in the future. Further subgroup analyses, which were not possible here because of the lack of power, are also needed in future studies, e.g. in order to determine specific platelet count thresholds in patients treated with antithrombotic drugs. Finally, this study was limited to newly diagnosed patients, to avoid confounding by ITP management: both the bleeding risk during the weeks following treatment initiation and the risk of bleeding according to treatment deserve to be measured in real-life settings.
In conclusion, platelet counts of < 20 9 10 9 L À1 and < 10 9 10 9 L À1 were thresholds with major increased risks of both any bleeding and mucosal bleeding at ITP diagnosis. Platelet count, female sex and exposure to NSAIDs should be considered in assessment of the risk of any bleeding. Exposure to anticoagulant drugs was a major risk factor for severe bleeding occurrence. A platelet count of < 20 9 10 9 L
, male sex and having comorbidities should also be considered as risk factors for severe bleeding at ITP diagnosis.
Supporting Information
Additional supporting information may be found online in the Supporting Information section at the end of the article: Fig. S1 . Receiver operating characteristic curves assessing the link between platelet count and occurrence of any bleeding, mucosal bleeding and severe bleeding in primary ITP patients (n = 254). Table S1 . Sensitivity, specificity and Youden index of platelet thresholds in primary ITP patients (n = 254).
